"Body composition outcomes in obesity pharmacotherapy: clinical significance and measurement challenges." Reviews in Endocrine and Metabolic Disorders
What This Means for Collagen Brands The GLP-1 consumer isnt going away
Research trials, including those supporting NICE guidance, have demonstrated that these medications may lead to modest improvements in cholesterol levels, particularly reductions in total cholesterol, LDL cholesterol, and triglycerides
A few additional strategies the chef employs revolve around the order of the meal, the texture of the foods and macronutrients
The data is less clear but increasingly supportive that some patients can space out their injections or step down to lower doses while maintaining their loss
This isn't unique to GLP-1 medications and can happen with any treatment that significantly improves blood sugar control